Sample comprehensive maps of responses to HCV and HIV-1 in 2 subjects coinfected with HCV and HIV-1. (A) From subject D7-02-18 (HCV VL, < 600 IU/mL; HIV-1 VL, < 50 copies/mL on antiretroviral therapy; CD4 T-cell count, 533/mm³), ELISpot detected 2 ex vivo specificities against HCV, 1 each in E2 and NS3, both previously described epitopes. Therefore, the cumulative magnitude of CD8⁺ IFN-γ–secreting cells was 987 SFC/10⁶ PBMCs or 0.099% of circulating PBMCs. In contrast, 15 specificities were detected against HIV-1, totaling 4610 SFC/10⁶ PBMCs or 0.46% of circulating PBMCs. (B) In subject C27-02M (HCV VL, 405 000 IU/mL; HIV-1 VL, 15 000 copies/mL; CD4 T-cell count, 528/mm³), ELISpot revealed 5 targeted HCV epitopes, all representing novel specificities, while HIV-1 responses also exceeded those against HCV both in breadth and magnitude.